Ying-ke Liang

Guangdong Key Laboratory Of Clinical Molecular
Guangzhou, 510180, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Retraction Note: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Retraction Note: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Journal: Molecular cancer

Published: March 21, 2023

Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer.

Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer.

Journal: Disease markers

Published: May 06, 2021

Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.

Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.

Journal: Cancer science

Published: February 06, 2021

Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Journal: Molecular cancer

Published: August 08, 2019

TRIB1 induces macrophages to M2 phenotype by inhibiting IKB-zeta in prostate cancer.

TRIB1 induces macrophages to M2 phenotype by inhibiting IKB-zeta in prostate cancer.

Journal: Cellular signalling

Published: January 01, 2019

Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer.

Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer.

Journal: International journal of cancer

Published: April 07, 2018

Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.

Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.

Journal: Journal of cellular biochemistry

Published: October 22, 2017

Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.

Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: June 28, 2017

MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Journal: Molecular cancer

Published: December 01, 2016

BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression.

BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression.

Journal: Oncology letters

Published: November 18, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026